Loading clinical trials...
Loading clinical trials...
Randomized, Double-Blind, Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy
Conditions
Interventions
AAV2-GDNF gene therapy
Sham (Placebo) Surgery
Locations
7
United States
University of California Irvine
Irvine, California, United States
Parkinson's Disease and Movement Disorders Center of Boca Raton
Boca Raton, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Quest Research Institute
Farmington Hills, Michigan, United States
NYU Langone Health
New York, New York, United States
The Ohio State University Medical Center
Columbus, Ohio, United States
Start Date
October 3, 2023
Primary Completion Date
August 1, 2026
Completion Date
August 1, 2028
Last Updated
January 30, 2026
NCT05748028
NCT04246437
NCT05121012
NCT03042988
NCT02429557
NCT04620382
Lead Sponsor
Brain Neurotherapy Bio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions